Lumos Pharma to Participate in December Investor Conferences
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, announced its participation in virtual investor conferences in December 2020. The company will engage in a fireside chat on November 23 and host one-on-one meetings on December 2 at the Piper Sandler Healthcare Conference. Additionally, Lumos will participate in a panel discussion at the Evercore ISI HealthCONx on December 3, where further one-on-one meetings will occur. The discussions will focus on Lumos' lead candidate, LUM-201, for Pediatric Growth Hormone Deficiency, which is an orally administered alternative to injections.
- None.
- None.
AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December:
| Piper Sandler Healthcare Conference | ||
| Date: | Monday, November 23, 2020 | |
| What: | Fireside chat with Lumos Pharma management | |
| Management will host virtual one-on-one meetings during the conference on Wednesday, December 2, 2020. An on-demand download of the fireside chat is available as of November 23rd on the Piper Sandler conference portal and under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website. | ||
| Evercore ISI HealthCONx | ||
| Date: | Thursday, December 3, 2020 | |
| Time: | 1:00-1:45PM ET | |
| What: | Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” – Chiasma, Crinetics, Lumos | |
| Management will host virtual one-on-one meetings throughout the day on Thursday, December 3, 2020. A live webcast of the panel discussion will be available on the company’s website under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website. | ||
Please contact your Piper Sandler and Evercore ISI sales representatives to register for these investor conferences and to schedule a virtual one-on-one meeting with the Lumos Pharma management team.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What conferences will Lumos Pharma attend in December 2020?
When is Lumos Pharma's fireside chat?
What is the focus of Lumos Pharma's panel discussion at HealthCONx?
What is Lumos Pharma's lead therapeutic candidate?
What is the significance of LUM-201 for patients?
